Improved therapies have allowed many patients with cancer to achieve complete remission, but they retain minimal residual disease (MRD), which causes relapse. This Opinion article argues that iterative detection, profiling and targeting of MRD could improve outcomes, including cure rates.
- Marlise R. Luskin
- Mark A. Murakami
- David M. Weinstock
